Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Schulze, Daniel ^a   Plohmann, Philipp ^a   Höbel, Sabrina ^a,b   Aigner, Achim ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Apoptosis; Colon carcinoma; Fgf bp; Gene targeting; Pei; Polyethylenimine; Rnai; Sirna

Indexed keywords

BINDING PROTEIN; CASPASE 3; CASPASE 7; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NANOPARTICLE; PROTEIN KINASE B; PROTEIN P21; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE; CELL PROLIFERATION; CELL PROTECTION; COLON CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN SECRETION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; WILD TYPE; XENOGRAFT;

ANIMALS; CARRIER PROTEINS; CELL PROLIFERATION; COLONIC NEOPLASMS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

MUS;

EID: 81555232414     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-144     Document Type: Article

References (61)

1. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocrine Related Cancer 2000, 7:165-197. 10.1677/erc.0.0070165, 11021964.
2. Wu D, Kan M, Sato GH, Okamoto T, Sato JD. Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. JBiolChem 1991, 266:16778-16785.
3. Tassi E, Al-Attar A, Aigner A, Swift MR, McDonnell K, Karavanov A, Wellstein A. Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. J Biol Chem 2001, 276:40247-40253.
4. Mongiat M, Otto J, Oldershaw R, Ferrer F, Sato JD, Iozzo RV. Fibroblast Growth Factor-binding Protein Is a Novel Partner for Perlecan Protein Core. J Biol Chem 2001, 276:10263-10271. 10.1074/jbc.M011493200, 11148217.
5. Beer HD, Bittner M, Niklaus G, Munding C, Max N, Goppelt A, Werner S. The fibroblast growth factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repair. Oncogene 2005, 24:5269-5277. 10.1038/sj.onc.1208560, 15806171.
6. Xie B, Tassi E, Swift MR, McDonnell K, Bowden ET, Wang S, Ueda Y, Tomita Y, Riegel AT, Wellstein A. Identification of the fibroblast growth factor (FGF)-interacting domain in a secreted FGF-binding protein by phage display. J Biol Chem 2006, 281:1137-1144.
7. Aigner A, Butscheid M, Kunkel P, Krause E, Lamszus K, Wellstein A, Czubayko F. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 2001, 92:510-517. 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H, 11304685.
8. Rak J, Kerbel RS. bFGF and tumor angiogenesis--back in the limelight?. Nat Med 1997, 3:1083-1084. 10.1038/nm1097-1083, 9334715.
9. Kurtz A, Wang HL, Darwiche N, Harris V, Wellstein A. Expression of a binding protein for FGF is associated with epithelial development and skin carcinogenesis. Oncogene 1997, 14:2671-2681. 10.1038/sj.onc.1201117, 9178765.
10. Aigner A, Ray PE, Czubayko F, Wellstein A. Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development. Histochem Cell Biol 2002, 117:1-11. 10.1007/s00418-001-0360-4, 11819092.
11. Kurtz A, Aigner A, Cabal-Manzano RH, Butler RE, Hood DR, Sessions RB, Czubayko F, Wellstein A. Differential regulation of a fibroblast growth factor-binding protein during skin carcinogenesis and wound healing. Neoplasia 2004, 6:595-602. 10.1593/neo.04214, 1531664, 15548369.
12. Ray R, Cabal-Manzano R, Moser AR, Waldman T, Zipper LM, Aigner A, Byers SW, Riegel AT, Wellstein A. Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis. Cancer Res 2003, 63:8085-8089.
13. Tassi E, Henke RT, Bowden ET, Swift MR, Kodack DP, Kuo AH, Maitra A, Wellstein A. Expression of a fibroblast growth factor-binding protein during the development of adenocarcinoma of the pancreas and colon. Cancer Res 2006, 66:1191-1198. 10.1158/0008-5472.CAN-05-2926, 16424058.
14. Okamoto T, Tanaka Y, Kan M, Sakamoto A, Takada K, Sato JD. Expression of fibroblast growth factor binding protein HBp17 in normal and tumor cells. In Vitro Cell Dev Biol Anim 1996, 32:69-71. 10.1007/BF02723035, 8907117.
15. Aigner A, Renneberg H, Bojunga J, Apel J, Nelson PS, Czubayko F. Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene 2002, 21:5733-5742. 10.1038/sj.onc.1205560, 12173043.
16. Czubayko F, Smith RV, Chung HC, Wellstein A. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chem 1994, 269:28243-28248.
17. Kagan BL, Henke RT, Cabal-Manzano R, Stoica GE, Nguyen Q, Wellstein A, Riegel AT. Complex regulation of the fibroblast growth factor-binding protein in MDA-MB-468 breast cancer cells by CCAAT/enhancer-binding protein beta. Cancer Res 2003, 63:1696-1705.
18. Harris VK, Liaudet-Coopman ED, Boyle BJ, Wellstein A, Riegel AT. Phorbol ester-induced transcription of a fibroblast growth factor-binding protein is modulated by a complex interplay of positive and negative regulatory promoter elements. J Biol Chem 1998, 273:19130-19139. 10.1074/jbc.273.30.19130, 9668098.
19. Zheng HQ, Zhou Z, Huang J, Chaudhury L, Dong JT, Chen C. Kruppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1. Oncogene 2009, 28:3702-3713. 10.1038/onc.2009.235, 19668233.
20. Stoppler H, Malerczyk C, Block K, Aigner A, Czubayko F. The human papillomavirus (HPV) 16 E6 oncoprotein leads to an increase in gene expression of the angiogenic switch molecule FGF-BP in non-immortalized human keratinocytes. Oncogene 2001, 20:7430-7436. 10.1038/sj.onc.1204957, 11704874.
21. Rosini P, Bonaccorsi L, Baldi E, Chiasserini C, Forti G, De Chiara G, Lucibello M, Mongiat M, Iozzo RV, Garaci E, et al. Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation. Prostate 2002, 53:310-321. 10.1002/pros.10164, 12430142.
22. Harris VK, Coticchia CM, Kagan BL, Ahmad S, Wellstein A, Riegel AT. Induction of the angiogenic modulator fibroblast growth factor-binding protein by epidermal growth factor is mediated through both MEK/ERK and p38 signal transduction pathways. J Biol Chem 2000, 275:10802-10811. 10.1074/jbc.275.15.10802, 10753873.
23. Aigner A, Malerczyk C, Houghtling R, Wellstein A. Tissue distribution and retinoid-mediated downregulation of an FGF-binding protein (FGF-BP) in the rat. Growth Factors 2000, 18:51-62. 10.3109/08977190009003233, 10831072.
24. Boyle BJ, Harris VK, Liaudet-Coopman ED, Riegel AT, Wellstein A. Differential regulation of a fibroblast growth factor-binding protein by receptor-selective analogs of retinoic acid. Biochem Pharmacol 2000, 60:1677-1684. 10.1016/S0006-2952(00)00507-4, 11077050.
25. Liaudet-Coopman EDE, Wellstein A. Regulation of gene expression of a binding protein for fibroblast growth factor by retinoic acid. JBiolChem 1996, 271:21303-21308.
26. Briones VR, Chen S, Riegel AT, Lechleider RJ. Mechanism of fibroblast growth factor-binding protein 1 repression by TGF-beta. Biochem Biophys Res Commun 2006, 345:595-601. 10.1016/j.bbrc.2006.04.052, 16690027.
27. Sherif ZA, Nakai S, Pirollo KF, Rait A, Chang EH. Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther 2001, 8:771-782. 10.1038/sj.cgt.7700361, 11687900.
28. Liaudet-Coopman EDE, Schulte AM, Cardillo M, Wellstein A. A tetracycline-responsive promoter system reveals the role of a secreted binding protein for FGFs during the early phase of tumor growth. Biochem Biophys Res Commun 1996, 229:930-937. 10.1006/bbrc.1996.1904, 8954996.
29. Czubayko F, Liaudet-Coopman EDE, Aigner A, Tuveson AT, Berchem G, Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch for human cancer. NatMed 1997, 3:1137-1140.
30. Abuharbeid S, Czubayko F, Aigner A. The fibroblast growth factor-binding protein FGF-BP. Int J Biochem Cell Biol 2005,
31. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995, 55:5187-5190.
32. Wellstein A, Lupu R, Zugmaier G, Flamm SL, Cheville AL, Delli Bovi P, Basilico C, Lippman ME, Kern FG. Autocrine growth stimulation by secreted Kaposi's fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth Differ 1990, 1:63-71.
33. Abuharbeid S, Apel J, Sander M, Fiedler B, Langer M, Zuzarte ML, Czubayko F, Aigner A. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun 2004, 321:403-412. 10.1016/j.bbrc.2004.06.160, 15358191.
34. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry 1992, 13:795-808. 10.1002/cyto.990130802, 1333943.
35. Hobel S, Koburger I, John M, Czubayko F, Hadwiger P, Vornlocher HP, Aigner A. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 2010, 12:287-300.
36. Hobel S, Prinz R, Malek A, Urban-Klein B, Sitterberg J, Bakowsky U, Czubayko F, Aigner A. Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery. Eur J Pharm Biopharm 2008,
37. Svoboda P. Off-targeting and other non-specific effects of RNAi experiments in mammalian cells. Curr Opin Mol Ther 2007, 9:248-257.
38. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 2009, 27:549-555. 2782465, 19465925.
39. Liu R, Zheng HQ, Zhou Z, Dong JT, Chen C. KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. J Biol Chem 2009, 284:16791-16798. 10.1074/jbc.M808919200, 2719315, 19411256.
40. Manoukian AS, Woodgett JR. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res 2002, 84:203-229.
41. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005, 12:461-466. 10.1038/sj.gt.3302425, 15616603.
42. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994, 54:1169-1174.
43. Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffleur T. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 2002, 98:498-504. 10.1002/ijc.10146, 11920608.
44. Rao S, Lowe M, Herliczek TW, Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998, 17:2393-2402. 10.1038/sj.onc.1202322, 9811471.
45. Tassi E, Walter S, Aigner A, Cabal-Manzano RH, Ray R, Reier PJ, Wellstein A. Effects on neurite outgrowth and cell survival of a secreted fibroblast growth factor binding protein upregulated during spinal cord injury. Am J Physiol Regul Integr Comp Physiol 2007, 293:R775-783. 10.1152/ajpregu.00737.2006, 17553847.
46. Chen C, Benjamin MS, Sun X, Otto KB, Guo P, Dong XY, Bao Y, Zhou Z, Cheng X, Simons JW, Dong JT. KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line. Int J Cancer 2006, 118:1346-1355. 10.1002/ijc.21533, 16184550.
47. Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY, Chung DH, Evers BM. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci USA 2008, 105:20315-20320. 10.1073/pnas.0810715105, 2629319, 19075230.
48. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241. 10.1016/S0092-8674(00)80405-5, 9346240.
49. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001, 21:893-901. 10.1128/MCB.21.3.893-901.2001, 86680, 11154276.
50. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001, 98:10983-10985. 10.1073/pnas.211430998, 58668, 11572954.
51. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789. 10.1038/378785a0, 8524413.
52. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006, 79:173-189. 10.1016/j.pneurobio.2006.07.006, 1618798, 16935409.
53. Mai W, Kawakami K, Shakoori A, Kyo S, Miyashita K, Yokoi K, Jin M, Shimasaki T, Motoo Y, Minamoto T. Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase. Clin Cancer Res 2009, 15:6810-6819. 10.1158/1078-0432.CCR-09-0973, 19903789.
54. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010, 29:4752-4765. 10.1038/onc.2010.221, 20531300.
55. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008, 8:967-975. 10.1038/nrc2540, 3140692, 18987634.
56. Li J, Shworak NW, Simons M. Increased responsiveness of hypoxic endothelial cells to FGF2 is mediated by HIF-1alpha-dependent regulation of enzymes involved in synthesis of heparan sulfate FGF2-binding sites. J Cell Sci 2002, 115:1951-1959.
57. Newman DR, Walsh E, Apparao KB, Sannes PL. Fibroblast growth factor-binding protein and N-deacetylase/N-sulfotransferase-1 expression in type II cells is modulated by heparin and extracellular matrix. Am J Physiol Lung Cell Mol Physiol 2007, 293:L1314-1320. 10.1152/ajplung.00211.2007, 17766586.
58. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unterman T, Hay N. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008, 14:458-470. 10.1016/j.ccr.2008.11.003, 3038665, 19061837.
59. Gibby KA, McDonnell K, Schmidt MO, Wellstein A. A distinct role for secreted fibroblast growth factor-binding proteins in development. Proc Natl Acad Sci USA 2009, 106:8585-8590. 10.1073/pnas.0810952106, 2689014, 19433791.
60. Lee HO, Choe H, Seo K, Lee H, Lee J, Kim J. Fgfbp1 is essential for the cellular survival during zebrafish embryogenesis. Mol Cells 2010, 29:501-507. 10.1007/s10059-010-0062-7, 20396962.
61. Aigner A. Nonviral in vivo delivery of therapeutic small interfering RNAs. Curr Opin Mol Ther 2007, 9:345-352.